Study guide

Substance Use, Medications & the ME's Prescription Review

NRCME National Registry of Certified Medical Examiners

Track your progress as you read

Finished sections get a check mark.

1 The National Registry, the ME Role & the Certification Test

What the NRCME Is & Why It Exists Who Can Become a Certified ME & Eligibility The NRCME Certification Test Itself Who Must Have a DOT Physical

2 The DOT Exam Process, Health History & Forms

The DOT Physical Workflow & the Medical Examiner's Responsibilities Driver Identification & Health-History Intake Diagnostic Tests & Specialist Referrals The Medical Examination Report - Form MCSA-5875 The Medical Examiner's Certificate (MCSA-5876) & Recordkeeping

3 Physical Examination Technique by Body Region

General Appearance, Vital Signs & Height/Weight/BMI Eyes and Ears Examination Mouth/Throat, Neck & Cardiovascular Exam Lungs, Chest & Abdomen Exam Spine, Extremities & Musculoskeletal Exam Neurologic Status, Mental Status & Urinalysis

4 Physical Qualification Standards I: Senses & Cardiorespiratory

Vision Standard & the Alternative Vision Standard Hearing Standard — 391.41(b)(11) Cardiovascular Standard — 391.41(b)(4) Respiratory Standard & Sleep Apnea — 391.41(b)(5) Hypertension Staging & Certification Intervals

5 Physical Qualification Standards II: Metabolic, Neuro, MSK & Behavioral

Diabetes: Insulin-Treated (ITDM) and Non-Insulin Standards Neurological Standard: Epilepsy, Seizures & Other Neurologic Conditions Musculoskeletal Standards & the Skill Performance Evaluation (SPE) Program Psychiatric & Mental-Health Standard Substance Use, Medications & the ME's Prescription Review

6 Determination, Certification Intervals, Risk Assessment & Exemptions

Making the Determination Certification Intervals and Durations Risk Assessment and Fitness for Duty Health Education and Counseling Federal Exemptions, Waivers, and Variances ME Professional Responsibilities, Follow-Up, and the National Registry

Substance Use, Medications & the ME's Prescription Review

Key Takeaways Explain This Topic AI

Marijuana other than FDA-approved products and state-licensed medical marijuana is Schedule I, so its use disqualifies under 391.41(b)(12)(i), whatever state law allows. State-licensed medical marijuana has been Schedule III since April 28, 2026 (91 FR 22714), so 391.41(b)(12)(ii) applies: its use disqualifies unless prescribed by a licensed medical practitioner familiar with the driver's history who advises it will not affect safe driving. FMCSA has not said whether a state medical-marijuana certification meets that.

CBD products containing less than 0.3% THC are not Schedule I substances and are not automatic grounds for disqualification under 391.41(b)(12).

391.41(b)(13) disqualifies a driver with a current clinical diagnosis of alcoholism.

Current FMCSA guidance does not list methadone or buprenorphine-naloxone treatment as automatically disqualifying; the examiner evaluates case-by-case with the prescribing clinician's input.

A driver with a DOT drug-and-alcohol program violation must complete a Substance Abuse Professional (SAP) evaluation and 49 CFR Part 40 return-to-duty process before resuming safety-sensitive duty.

Last updated: November 2026

Schedule I Drugs — 391.41(b)(12)

391.41(b)(12) disqualifies a driver who uses any drug or substance identified in 21 CFR 1308.11 (Schedule I) , an amphetamine, a narcotic, or other habit-forming drug — with a narrow exception for a legally prescribed medication that is not a Schedule I substance, where the ME determines, after consulting the prescribing clinician, that it will not adversely affect safe operation.

Marijuana Under 391.41(b)(12)

Marijuana other than FDA-approved products and state-licensed medical marijuana is Schedule I (including extracts above 0.3% THC), so its use disqualifies under 391.41(b)(12)(i), whatever state law allows. State-licensed medical marijuana has been Schedule III since April 28, 2026 (91 FR 22714), so 391.41(b)(12)(ii) applies: its use disqualifies unless prescribed by a licensed medical practitioner familiar with the driver's history who advises it will not affect safe driving. FMCSA has not said whether a state medical-marijuana certification meets that. Separately, DOT drug testing is unchanged: a state medical-marijuana authorization is not a legitimate medical explanation for a positive test (49 CFR 40.151(e)). CBD products containing less than 0.3% THC are not Schedule I substances , so their use is not automatic grounds for disqualification, though the ME should still counsel drivers that mislabeled CBD products can carry enough THC to trigger a positive drug test, an operational risk distinct from the certification standard itself.

Alcoholism — 391.41(b)(13)

391.41(b)(13) disqualifies a driver with a current clinical diagnosis of alcoholism. The word "current" matters: a documented history of alcohol use disorder that is in sustained remission, with treatment and monitoring, is evaluated differently from an active diagnosis — the ME weighs the specific clinical picture rather than treating any past diagnosis as a permanent bar.

Methadone and Medication-Assisted Treatment: A Judgment Call, Not an Automatic Bar

Older guidance once treated methadone as automatically disqualifying; current FMCSA guidance does not list methadone in the regulation as precluding certification . The same is true of buprenorphine/naloxone combination products such as Suboxone. Neither is a bright-line CFR bar the way marijuana use is. Instead, the ME evaluates the treatment case-by-case : obtaining the opinion of the prescribing clinician, who knows the driver's history and the specifics of the regimen, on whether the medication-assisted treatment will adversely affect the driver's ability to operate a CMV safely. In practice, many examiners remain cautious about certifying drivers on methadone maintenance because of sedation and cognitive-effect concerns, but that caution reflects individualized clinical judgment, not an automatic regulatory disqualification.

Substance / condition CFR cite Disqualifying?

Schedule I drugs, incl. non-medical marijuana 391.41(b)(12)(i) Yes, automatic

State-licensed medical marijuana (Schedule III) 391.41(b)(12)(ii) Yes unless prescribed as (b)(12)(ii) requires; FMCSA has not said whether a state certification counts

  • CBD, under 0.3% THC 391.41(b)(12) Not automatic
  • Amphetamine / narcotic / habit-forming drug without valid prescription 391.41(b)(12) Yes, automatic
  • Legally prescribed non-Schedule-I drug 391.41(b)(12) ME judgment, with prescriber input
  • Methadone / buprenorphine-naloxone (MAT) 391.41(b)(12) ME judgment, case-by-case
  • Current clinical diagnosis of alcoholism 391.41(b)(13) Yes, automatic
  • Alcohol use disorder history, sustained remission 391.41(b)(13) ME judgment
  • SAP Evaluation and the Return-to-Duty Process

A driver who has a DOT drug-and-alcohol testing program violation cannot return to safety-sensitive duty on the ME's certification alone. Federal rule (49 CFR Part 40) requires completion of a Substance Abuse Professional (SAP) evaluation and a documented return-to-duty process before the driver resumes CMV operation. The SAP evaluates the driver, recommends education or treatment, confirms compliance, and only then may the driver take a negative return-to-duty test followed by a follow-up testing plan set by the SAP. The ME reviews SAP results and return-to-duty status as part of the driver's documented history — the same ancillary-documentation discipline covered under the Medical Examination Report — but the ME does not conduct the SAP evaluation itself; that is a distinct, specialized role under Part 40.

The ME's General Medication-Review Role

At every DOT physical, the ME reviews all prescription, over-the-counter, and supplement use the driver reports on the health history, not just the substances named in (b)(12) and (b)(13). Medication classes that routinely draw closer scrutiny include:

Opioid analgesics — sedation, slowed reaction time, and, if habit-forming without a valid ongoing prescription, potential (b)(12) exposure

Benzodiazepines and other sedative-hypnotics — sedation and next-day impairment even with therapeutic dosing

Sedating antihistamines and sleep aids — often OTC, and easy for a driver to under-report as "not a real medication"

Stimulants (ADHD treatment, some weight-loss agents) — reviewed under the same legally-prescribed, non-Schedule-I framework discussed for ADHD in the psychiatric standard

Anticoagulants and antiplatelet agents — not sedating, but relevant to injury and bleeding risk in the event of a crash, and worth noting for the health-education counseling covered later in this guide

The task in each case is the same: identify anything sedating, cognitively impairing, or otherwise incompatible with safe CMV operation; consult the prescriber rather than disqualifying on the medication name alone; and counsel the driver to report any new medication before the next exam. This ongoing medication surveillance is one of the clearest places where the ME's exam-room judgment, rather than a fixed number, determines the outcome.

The underlying theme across 391.41(b)(12) and (b)(13) is the same distinction that runs through this entire chapter: a small number of standards (Schedule I use, a current alcoholism diagnosis) are bright-line and automatic, while most of the surrounding medication and substance questions are resolved through the ME's individualized clinical judgment, informed by the prescribing clinician, rather than a fixed rule that can be looked up and applied mechanically.